CN1266421B - 抗癌化合物 - Google Patents

抗癌化合物 Download PDF

Info

Publication number
CN1266421B
CN1266421B CN98807751.5A CN98807751A CN1266421B CN 1266421 B CN1266421 B CN 1266421B CN 98807751 A CN98807751 A CN 98807751A CN 1266421 B CN1266421 B CN 1266421B
Authority
CN
China
Prior art keywords
cells
euphorbia
cancer
compound
sap
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN98807751.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN1266421A (zh
Inventor
詹姆斯·H·艾尔沃德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
April 30 2003 LLC
Leo Pharma AS
Original Assignee
Peplin Biotech Pty Ltd
Leo Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=3802927&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1266421(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Peplin Biotech Pty Ltd, Leo Pharma AS filed Critical Peplin Biotech Pty Ltd
Publication of CN1266421A publication Critical patent/CN1266421A/zh
Application granted granted Critical
Publication of CN1266421B publication Critical patent/CN1266421B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/47—Euphorbiaceae (Spurge family), e.g. Ricinus (castorbean)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN98807751.5A 1997-08-19 1998-08-19 抗癌化合物 Expired - Lifetime CN1266421B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AUPO8640 1997-08-19
AUPO8640A AUPO864097A0 (en) 1997-08-19 1997-08-19 Anti-cancer compounds
PCT/AU1998/000656 WO1999008994A1 (en) 1997-08-19 1998-08-19 Anti-cancer compounds

Publications (2)

Publication Number Publication Date
CN1266421A CN1266421A (zh) 2000-09-13
CN1266421B true CN1266421B (zh) 2014-06-18

Family

ID=3802927

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98807751.5A Expired - Lifetime CN1266421B (zh) 1997-08-19 1998-08-19 抗癌化合物

Country Status (17)

Country Link
US (4) US6432452B1 (enExample)
EP (1) EP1015413B1 (enExample)
JP (3) JP2001515059A (enExample)
CN (1) CN1266421B (enExample)
AT (1) ATE397580T1 (enExample)
AU (1) AUPO864097A0 (enExample)
BE (1) BE2013C026I2 (enExample)
BR (1) BR9811327A (enExample)
CA (1) CA2301082C (enExample)
CY (2) CY1108303T1 (enExample)
DE (1) DE69839586D1 (enExample)
DK (1) DK1015413T3 (enExample)
ES (1) ES2308810T3 (enExample)
HU (2) HU228862B1 (enExample)
LU (1) LU92185I2 (enExample)
PT (1) PT1015413E (enExample)
WO (1) WO1999008994A1 (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO864097A0 (en) * 1997-08-19 1997-09-11 Peplin Pty Ltd Anti-cancer compounds
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
US7078434B1 (en) * 1999-08-12 2006-07-18 Societe De Conseils De Recherches Et D'applications Scientifiques Sas Use of Ginkgo extract
AU748542B2 (en) * 2000-06-07 2002-06-06 Leo Laboratories Limited Therapeutic agents - III
AUPQ801700A0 (en) * 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
AUPQ923100A0 (en) 2000-08-07 2000-08-31 Peplin Research Pty Ltd Treatment of prostate cancer
US6923993B2 (en) * 2001-12-12 2005-08-02 Nicholas J. Donato Process of isolating extract from the Euphorbia obesa plant and methods for using the same
MY139563A (en) 2002-09-04 2009-10-30 Bristol Myers Squibb Co Heterocyclic aromatic compounds useful as growth hormone secretagogues
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7375228B2 (en) 2003-03-17 2008-05-20 Takeda San Diego, Inc. Histone deacetylase inhibitors
EP2272951B1 (en) 2003-10-14 2014-07-23 Baxter International Inc. Vitamin k epoxide recycling polypeptide vkorc1, a therapeutic target of coumarin and their derivatives
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
AU2005214979B2 (en) * 2004-02-17 2009-09-10 The Uab Research Foundation Cytotoxin compound and method of isolation
US20070155685A1 (en) * 2004-02-27 2007-07-05 Karl-Hermann Schlingensiepen Pharmaceutical composition
DE102004044428A1 (de) * 2004-09-14 2006-03-30 Toximed Gmbh Verfahren und pharmazeutischer Wirkstoff zur Bekämpfung von Plasmodien
AU2005316185B2 (en) * 2004-12-13 2012-04-12 Leo Laboratories Limited Treatment of solid cancers
WO2006063382A1 (en) * 2004-12-13 2006-06-22 Peplin Research Pty Ltd Treatment of solid cancers
US7642275B2 (en) 2004-12-16 2010-01-05 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2008540574A (ja) 2005-05-11 2008-11-20 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
WO2006134609A2 (en) * 2005-06-16 2006-12-21 Mmi Corporation Novel anticancer agent, methods for obtaining the same and pharmaceutical compositions thereof
US7655620B2 (en) * 2005-07-07 2010-02-02 Cancure Laboratories, Llc Use of one or more metal carriers to selectively kill mammalian cells
CA2615105A1 (en) * 2005-07-14 2007-01-25 Takeda San Diego, Inc. Histone deacetylase inhibitors
US9597311B2 (en) * 2005-09-27 2017-03-21 Robert Benson Aylor Suppression and prevention of tumors
CN101360506A (zh) * 2005-11-25 2009-02-04 派普林研究股份有限公司 创伤愈合的方法
WO2007065925A2 (de) * 2005-12-07 2007-06-14 Toximed Gmbh Zusammensetzung zur behandlung von melanomen und hautunreinheiten sowie kosmetisches hautpflegemittel
GB0525680D0 (en) 2005-12-16 2006-01-25 Peplin Ltd Therapeutic compositions
EP1976835A2 (en) * 2006-01-13 2008-10-08 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20080069809A1 (en) * 2006-04-20 2008-03-20 Ogbourne Steven M Compositions and methods for the diagnosis and treatment of cancer
US20080207738A1 (en) * 2007-02-28 2008-08-28 Cancure Laboratories, Llc Drug combinations to treat drug resistant tumors
TWI389699B (zh) * 2009-02-13 2013-03-21 高雄醫學大學 用於誘導細胞凋亡之樟芝子實體乙醇萃取物及其製備方法
PL2395993T3 (pl) * 2009-02-13 2017-10-31 Leo Laboratories Ltd Zabieg na skórę
CN102844294A (zh) 2010-04-16 2012-12-26 利奥制药有限公司 结晶巨大戟二萜醇甲基丁烯酸酯
WO2011139172A1 (en) * 2010-05-06 2011-11-10 Goran Milosavljevic Diterpene compounds with antineoplastic activities and pharmaceutical compositions comprising same
JP6116481B2 (ja) * 2010-10-25 2017-04-19 ニーキ ファーマ インコーポレイテッド 神経内分泌腫瘍を治療する方法
WO2012080466A2 (en) 2010-12-17 2012-06-21 Leo Pharma A/S Ingenols for treating seborrheic keratosis
EP2655311A1 (en) 2010-12-22 2013-10-30 Leo Laboratories Limited Ingenol-3-acylates i
TWI548616B (zh) 2010-12-22 2016-09-11 理奧實驗有限公司 巨大戟萜醇－３－醯化物iii及巨大戟萜醇－３－胺基甲酸酯化物
JP5911508B2 (ja) 2010-12-22 2016-04-27 レオ・ラボラトリーズ・リミテッドＬｅｏ Ｌａｂｏｒａｔｏｒｉｅｓ Ｌｉｍｉｔｅｄ ３−アシル−インゲノールｉｉ
US8858953B2 (en) 2011-05-09 2014-10-14 Yu-Hwa Peter Sheng Herbal composition for treating cancer
WO2012176015A1 (en) 2011-06-24 2012-12-27 Leo Pharma A/S Methods for treating uv-damaged skin and scc tumors and for removing tattoos with topical ingenol mebutate
KR101374760B1 (ko) * 2011-10-26 2014-03-17 한국생명공학연구원 포볼 타입의 디테르펜 화합물 및 이를 포함하는 바이러스 감염 질환의 치료 또는 예방용 약학적 조성물
US9422309B2 (en) 2012-06-26 2016-08-23 Leo Laboratories Limited 3-O-heteroaryl-ingenol
CN103655674A (zh) * 2012-09-11 2014-03-26 清华大学深圳研究生院 乳浆大戟提取物及其制备方法和应用
KR101578404B1 (ko) 2014-03-18 2015-12-18 원광대학교 산학협력단 대극속 식물 추출물 또는 분획물을 유효성분으로 포함하는 암 예방 또는 치료용 조성물
US9948261B2 (en) * 2014-11-20 2018-04-17 Tymphany Hk Limited Method and apparatus to equalize acoustic response of a speaker system using multi-rate FIR and all-pass IIR filters
CN106916580A (zh) * 2015-10-01 2017-07-04 钱秀英 一种基于生物显色技术以服务于物联网的储物箱
CN106905950A (zh) * 2015-10-01 2017-06-30 钱秀英 一种用于判断时间的生物显色剂
US12502369B2 (en) 2015-11-11 2025-12-23 K-Gen, Inc. Methods of cancer treatment
US9758786B2 (en) 2016-02-09 2017-09-12 Autotelic, Llc Compositions and methods for treating pancreatic cancer
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
MY197240A (en) 2016-09-02 2023-06-07 Thailand Center Of Excellence For Life Sciences Method for preparing an extract of hevea latex and composition thereof
CN110663685B (zh) * 2019-10-23 2021-10-12 扬州大学 一种介孔二氧化硅负载ppte的纳米农药制剂
CN112441924B (zh) * 2020-12-11 2024-05-03 浙江工业大学 巨大戟二萜化合物及其提取方法与应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330094A1 (de) * 1988-02-25 1989-08-30 Eszter geb. Szénási Tamás Verwendung der Pflanze Euphorbia hirta L. und ihrer Extrakte sowie ihrer Wirkstoffe

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2902506A1 (de) * 1979-01-23 1980-07-24 Deutsches Krebsforsch Verwendung von nicht oder nur gering irritierenden und/oder promovierenden diterpenalkoholen und von derivaten davon als antineoplastische mittel
JPS5813571A (ja) * 1981-07-14 1983-01-26 Sagami Chem Res Center ジヒドロフラン誘導体及びその製造方法
US4418064A (en) * 1982-09-29 1983-11-29 The United States Of America As Represented By The Secretary Of Agriculture Chemotherapeutically active maytansinoids: treflorine, trenudine, and N-methyltrenudone
US4560774A (en) 1982-11-17 1985-12-24 Arizona State University Macrocyclic lactones
US5886019A (en) 1986-06-11 1999-03-23 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. F.
US5145842A (en) 1986-06-11 1992-09-08 Alder Research Center Limited Partnership Protein kinase c. modulators. d.
US5643948A (en) 1986-06-11 1997-07-01 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. K.
US5716968A (en) 1986-06-11 1998-02-10 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. H.
US5891906A (en) 1986-06-11 1999-04-06 Procyon Pharmaceuticals, Inc. Polyacetate-derived phorboids having anti-inflammatory and other uses
US5750568A (en) 1986-06-11 1998-05-12 Procyon Pharmaceuticals, Inc. Protein kinase C Modulators. L.
US5886017A (en) 1986-06-11 1999-03-23 Procyon Pharmaceuticals, Inc. Protein kinase C modulators. E.
IL82811A0 (en) 1986-06-11 1987-12-20 Alder Res Center Corp Anti-inflammatory compositions containing methanol derivatives and novel compounds contained therein
US5891870A (en) 1986-06-11 1999-04-06 Procyon Pharmaceuticals, Inc. Protein kinase C modulators Q
DE4102054A1 (de) 1991-01-24 1992-07-30 Geb Szenasi Tamas Verwendung der pflanze euphorbia hirta l. und ihrer extrakte sowie ihrer wirkstoffe
CN1047084C (zh) 1993-03-30 1999-12-08 刘振宪 人参口服液及其制造方法
US6593371B1 (en) 1993-05-19 2003-07-15 Jeff J. Staggs Treatment for wart and related disorders
CN1048164C (zh) 1993-08-24 2000-01-12 吴雪姣 复方菝葜口服液
JP2913451B2 (ja) 1994-06-22 1999-06-28 株式会社イナックス 防水パンの高さ調整構造
JPH08245505A (ja) 1994-09-09 1996-09-24 Tosoh Corp ジテルペン誘導体、その製造法及びそれを有効成分として含有する抗腫瘍剤
JPH08176002A (ja) * 1994-12-27 1996-07-09 Kao Corp 細胞接着抑制剤
CN1070372C (zh) 1995-02-15 2001-09-05 赵国强 强力抗癌膏及其制造方法
WO1997015575A1 (en) 1995-10-27 1997-05-01 Procyon Pharmaceuticals, Inc. Protein kinase c modulators. y.
CN1058620C (zh) * 1995-11-12 2000-11-22 卢颖 一种治疗癌症的外用中成药及配备生产工艺
JPH08268961A (ja) * 1996-02-28 1996-10-15 Procyon Pharmaceut Inc 抗炎症組成物
US5932613A (en) * 1996-07-03 1999-08-03 Millennium Pharmaceuticals, Inc. Anticancer agents
AUPO864097A0 (en) * 1997-08-19 1997-09-11 Peplin Pty Ltd Anti-cancer compounds
JP2001139468A (ja) 1999-11-11 2001-05-22 Lead Chemical Co Ltd 抗ウイルス作用を有するホルボール誘導体
US6444555B2 (en) * 1999-12-07 2002-09-03 Advanced Micro Devices, Inc. Method for establishing ultra-thin gate insulator using anneal in ammonia
AUPQ801700A0 (en) 2000-06-07 2000-06-29 Peplin Research Pty Ltd Enzyme and viral activation
AUPQ923100A0 (en) 2000-08-07 2000-08-31 Peplin Research Pty Ltd Treatment of prostate cancer
US20030185168A1 (en) * 2002-03-28 2003-10-02 Yu-Wei Tung Topology of frequency converting blocks of wireless lan access point

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0330094A1 (de) * 1988-02-25 1989-08-30 Eszter geb. Szénási Tamás Verwendung der Pflanze Euphorbia hirta L. und ihrer Extrakte sowie ihrer Wirkstoffe

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
j.jakupovic et.al.diterpens from euphorbia peplus.phytochemistry47 8.1998,47(8),1601-1609. *

Also Published As

Publication number Publication date
EP1015413A1 (en) 2000-07-05
HUS1300063I1 (hu) 2019-11-28
AU8721798A (en) 1999-03-08
AUPO864097A0 (en) 1997-09-11
ATE397580T1 (de) 2008-06-15
US20050003031A1 (en) 2005-01-06
US6844013B2 (en) 2005-01-18
JP2015007130A (ja) 2015-01-15
CA2301082C (en) 2009-02-03
CY2013020I1 (el) 2019-11-27
EP1015413A4 (en) 2004-01-28
PT1015413E (pt) 2008-09-15
HUP0004262A1 (hu) 2001-08-28
LU92185I2 (fr) 2014-04-23
US6787161B2 (en) 2004-09-07
ES2308810T3 (es) 2008-12-01
US6432452B1 (en) 2002-08-13
US7410656B2 (en) 2008-08-12
CY2013020I2 (el) 2019-11-27
EP1015413B1 (en) 2008-06-04
BR9811327A (pt) 2000-09-19
US20020076457A1 (en) 2002-06-20
BE2013C026I2 (en) 2018-06-05
DK1015413T3 (da) 2008-09-22
CY1108303T1 (el) 2014-02-12
CN1266421A (zh) 2000-09-13
US20010051644A1 (en) 2001-12-13
JP2012031212A (ja) 2012-02-16
WO1999008994A1 (en) 1999-02-25
DE69839586D1 (de) 2008-07-17
HU228862B1 (en) 2013-06-28
JP2001515059A (ja) 2001-09-18
AU736230B2 (en) 2001-07-26
CA2301082A1 (en) 1999-02-25

Similar Documents

Publication Publication Date Title
US7410656B2 (en) Anti-cancer compounds
Wu et al. Kaempferol attenuates doxorubicin-induced renal tubular injury by inhibiting ROS/ASK1-mediated activation of the MAPK signaling pathway
Gomes et al. Anti-inflammatory and antioxidant activity of hydroethanolic extract of Spondias mombin leaf in an oral mucositis experimental model
Eloutify et al. Bioactive fraction from Plumeria obtusa L. attenuates LPS-induced acute lung injury in mice and inflammation in RAW 264.7 macrophages: LC/QToF-MS and molecular docking
JP2004517101A (ja) ヒペリクム・ペルフォラツム・エルの改良された安定な抽出物、その調製方法および局所薬剤としての用途
Belhadj Slimen et al. Bioactive compounds of prickly pear [Opuntia ficus-indica (L.) Mill.]
Lan et al. Phytochemistry, pharmacological activities, toxicity and clinical application of Momordica cochinchinensis
Yusufoglu et al. Anti-inflammatory and wound healing activities of herbal gel containing an antioxidant Tamarix aphylla leaf extract
Hu et al. Hepatoprotective effect of flavonoid-enriched fraction from Cyclocarya paliurus leaves on LPS/D-GalN-induced acute liver failure
Setiawan et al. Synergistic anti-inflammatory effects of Curcuma xanthorrhiza rhizomes and Physalis angulata herb extract on lipopolysaccharide-stimulated RAW 264.7 cells
Ukwubile et al. Role of Chitosan-Loaded solanine glycoalkaloid from Solanum scabrum mill. Leaf extract as Anti-Inflammatory and in vitro anticancer agents
AU750624B2 (en) Anti-cancer compounds-I
Shehab et al. Chemical composition, docking simulations and burn wound healing effect of Micromeria fruticosa extract and its isolated flavonoidal compound.
AU750628B2 (en) Anti-cancer compounds-II
Datta et al. Plumbago zeylinica Linn.(Chitrak)-Review as rasayan (rejuvenator/antiaging)
AU748545B2 (en) Anti-cancer compounds-III
Szumlak et al. Creating a reliable zebrafish model for studying inflammation: Exploring the therapeutic potential of xanthohumol
Patel et al. Review on Lawsonia inermis Linn.: An Update
Edo et al. The phytochemistry and pharmacology of Bidens alba
Chandrasekar et al. In Vitro Wound Healing and Anticancer Effects of Ixora coccinea in Malignant Melanoma Cell Lines
Dlamini Isolation and characterization of bio-active compounds from Lippia javanica
Mohammed et al. Protective effect of Carica papaya leaf extract against dental pulp damage induced by gamma irradiation
To et al. Antioxidant Levels and Inhibition of Cancer Cell Proliferation In-vitro by Extracts from Peltophorum pterocarpum Collected in Vietnam
Ceravolo HEALTH POTENTIAL OF ALOE VERA AND POLYDEOXYRIBONUCLEOTIDE (PDRN) AGAINST OXIDATIVE STRESS INDUCED CORNEAL DAMAGE: AN IN VITRO MODEL OF FUCHS ENDOTHELIAL CORNEAL DYSTROPHY
Masci EAU de PHILAE

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: LEO LAB LTD.

Free format text: FORMER OWNER: APRIL 30, 2003 CO., LTD.

Effective date: 20130715

Owner name: APRIL 30, 2003 CO., LTD.

Free format text: FORMER OWNER: PEPLIN RESEARCH CO., LTD.

Effective date: 20130715

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130715

Address after: Dublin, Ireland

Applicant after: LEO PHARMA A/S

Address before: Denmark and Rupp

Applicant before: April 30, 2003 LLC

Effective date of registration: 20130715

Address after: Denmark and Rupp

Applicant after: April 30, 2003 LLC

Address before: Australia Lucia

Applicant before: Pepling Research Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20140618